BRAF and colorectal carcinoma: As ALK fusions have recently been shown to be involved in resistance to BRAF inhibitors in melanoma [88], combinatorial therapies combining ALK inhibitors with other targeted therapies might lead to some therapeutic benefit in a subset of CRC patients.